RSS Newsfeeds

See all RSS Newsfeeds

Global Regions

United States ( XML Feed )

Aug 19, 2016 11:16 AM ET

Archived: Phoenix Life Sciences to Acquire Phoenix Bio Pharmaceuticals

Disclosure NewswireTM

iCrowdNewswire - Aug 19, 2016


DENVER, CO – Phoenix Life Sciences, Inc. (“Phoenix Life“) a private company within the healthcare and biotech industries, is pleased to announce that a Letter of Intent has been executed for the acquisition of Phoenix Bio Pharmaceuticals Corporation (“Phoenix Bio Pharmaceuticals“). Phoenix Bio Pharmaceuticals is a privately held company with a focus on the research, development and commercialization of intellectual property assets. The current intellectual property portfolio consists of condition-specific formulations, multiple proprietary compounds, extraction technology, and delivery systems for medical cannabis products.

Phoenix Life Sciences recently announced that it had entered into agreement for merger with MediJane Holdings, Inc. (“MJMD“), a publicly traded corporation with the assistance of NMS Capital Advisors, LLC. (“NMS Capital“). NMS Capital is a registered broker dealer headquartered in Beverly Hills, California that’s been appointed as MJMD’s exclusive financial advisor. As part of this engagement NMS Capital has been advising MJMD on its current plans involving industry repositioning, expansion, acquisitions and a greater access to the capital markets.

The acquisition of Phoenix Bio Pharmaceuticals will help secure ownership of certain intellectual property assets, previously licensed by MJMD and further expands the intellectual property assets which can be utilized by Phoenix Life and its affiliates. Upon completion of this transaction, Phoenix Life will acquire a diverse cannabinoid and combination therapy intellectual property portfolio. Where viable, Phoenix Life intends to pursue United States patent registrations for certain of the intellectual property assets. Based on the current portfolio, this represents up to fifty (50) potential individual patent filings which will be designed to protect the intellectual property in the areas of extraction technology, proprietary compounds, and delivery systems.

The acquisition is designed to position Phoenix Life Sciences to lead the build out of United States domestic and international production and distribution facilities for disruptive healthcare solutions. Providing opportunities for partnerships in the evolving medical cannabis industries in the United States, but also in countries like Australia, Canada and Germany. Allowing doctors, pharmacies and other medical professionals to enhance patient care with dosing accuracy with a choice of delivery mechanisms.

Vince Coviello, President and Chief Investment Officer of Phoenix Life said, “Gaining ownership of the intellectual property will give us greater leverage to open up doors and expand our capacity to bring cannabinoid oriented therapy to the patients who need it, both nationally and internationally as the regulatory frameworks open up.

“By being able to combine the companies into a single global player in the evolving healthcare industry, we are positioning ourselves to serve the growing interests of governments in advancing healthcare with the inclusion of medical cannabis programs; providing doctors with real solutions for patient dosing and delivery systems; and most importantly providing patients with safe and legal access to clinically proven plant based compounds, maximizing results and minimizing side effects, Continued Coviello.

About Phoenix Life Sciences, Inc.

Phoenix Life Sciences is a healthcare solutions company. Its business is to research, produce, and distribute products around the glove that target and treat the following seven major categories of medical conditions: pain, cancer, psychological, gastrointestinal, autoimmune, neurological, and sleep disorders. These categories include conditions that effect hundreds of millions of patients worldwide. Phoenix Life Sciences intends to build an integrated healthcare organization by creating products and programs using emerging biological products such as cannabinoid and other plant extracts. Delivering these programs through managed agriculture, pharmaceutical production and physician education and distribution networks.


Phoenix Life Sciences, Inc.
Investor Relations
Phone: 720-575-6066
E-mail: info@phoenix.life

For more information, visit www.phoenix.life

About MediJane Holdings Inc. (MJMD)

MediJane Holdings, Inc. recently announced that a Letter of Intent for a reorganization and merger between MediJane and Phoenix Life Sciences has been executed. The vision of the merger is to develop an international network of production, research, testing facilities for distribution of disruptive medical solutions. Following the merger, the company will be known as Phoenix Life Sciences.


MediJane Holdings, Inc.
Investor Relations
Phone: 720-442-7242
E-mail: investor.relations@mjmd.net

For more information, visit www.medijane.co

About NMS Capital Advisors

Founded in 2006, NMS Capital Advisors is a leading global focused investment banking and advisory firm providing an array of Global Capital Advisory™ services which include Mergers &Aquisitions, Corporate Finance and Strategic Advisory services to both public and private clients located in the United States, Asia and Europe. The NMS Capital Investment Banking consists of seasoned professionals with in-depth domestic and international capital markets transaction experience. NMS is registered with the Securities and Exchange Commission and the Financial Regulatory Authority.


Trevor Saliba, NMS Capital Advisors
Phone: 800-716-2080
Email: trevor.saliba@nmscapital.com

For more information, visit www.nmsadvisors.com

Information contained in this presentation regarding MediJane Holdings, Inc. and Phoenix Life Sciences, Inc. (the “Companies“) may constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements. The words “plan”, “forecast”, “anticipates”, “estimate”, “project”, “intend”, “expect”, “should”, “believe,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to, known and unknown risks, uncertainties and other factors which could cause the Companies actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Companies filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to the Companies herein are expressly qualified in their entirety by the above-mentioned cautionary statement. The companies disclaim any obligation to update forward-looking statements contained in this press release, except as may be required by law.


Contact Information:

Investor Relations

View Related News >